**Question:** Multibacillary leprosy is treated by

A. Streptomycin
B. Dapsone
C. Clofazimine
D. Rifampicin

**Correct Answer:** D. Rifampicin

**Core Concept:**
Multibacillary leprosy is a more severe form of leprosy characterized by a high bacillary load and involvement of multiple organs. It requires a combination of antibiotics to effectively target the wide range of Mycobacterium leprae strains present in the patient.

**Why the Correct Answer is Right:**
Rifampicin is a potent antibiotic that targets DNA-dependent RNA polymerase, which is essential for bacterial transcription. In the context of leprosy, rifampicin effectively kills the intracellular M. Leprae bacilli present in macrophages and dendritic cells within the host. Rifampicin is combined with other drugs like clofazimine, dapsone, and/or streptomycin, which target different aspects of the disease, such as immunomodulation, bacteriostasis, and cell wall synthesis, respectively.

**Why Each Wrong Option is Incorrect:**

A. Streptomycin: Although streptomycin has activity against M. Leprae, it is less effective than rifampicin and has higher toxicity. It is mainly used in combination with other drugs, especially in paucibacillary leprosy cases.

B. Dapsone: Dapsone is an effective drug for leprosy, but it is not as potent as rifampicin, clofazimine, and isoniazid. Combination therapy is crucial for treating multibacillary leprosy, and rifampicin is a vital component of this combination.

C. Clofazimine: Clofazimine is a potent drug against leprosy, but it is less effective than rifampicin, especially in multibacillary leprosy cases. Rifampicin is the primary drug for multibacillary leprosy due to its potent bactericidal activity and synergistic effect with other drugs in the combination therapy.

**Clinical Pearl:**

Multibacillary leprosy requires a combination of antibiotics to effectively reduce the high bacillary load and prevent drug-resistant strains. Rifampicin is a critical component of this combination therapy, along with clofazimine, dapsone, and/or streptomycin, depending on the disease stage and patient's response. By combining these drugs, the risk of drug resistance is minimized, and the treatment response is optimized.